Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Is Bio-adrenomedullin (Bio-ADM) a Prognostic Factor in Patients With COVID-19 Treated in the ICU?

NCT04813939 is registered in ClinicalTrials.gov with Medical University of Warsaw as lead sponsor.

NCT NCT04813939
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04813939 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Is Bio-adrenomedullin (Bio-ADM) a Prognostic Factor in Patients With COVID-19 Treated in the ICU?
Lead sponsor
Medical University of Warsaw
Phase
Observational
Overall status
Terminated
Start date
March 22, 2021
Completion date
January 31, 2022
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19